Perspective Therapeutics (CATX) investor relations material

Platform differentiation and technology

• Alpha emitter approach using Lead-212 targets tumors with high precision, aiming for improved safety and efficacy over traditional therapies.

• Proprietary chelator design with net neutral charge promotes kidney excretion and retains daughter isotopes, reducing off-target toxicity.

• Preclinical dosimetry and animal studies guide target selection and dosing to maximize tumor uptake and minimize healthy tissue exposure.

• Safety and efficacy are prioritized equally in drug design, with benefits expected to extend across the pipeline.

Clinical data and program updates

• Over 100 patients dosed across trials, demonstrating robust supply and operational capability.

• VMT-α-NET lead program shows a 43% response rate in cohort two (intent-to-treat), rising to 50% in SSTR2 expressers, outperforming existing NET therapies.

• Higher dose cohorts (cohort three and four) are being explored due to strong safety profile and absence of maximum tolerated dose.

• Deepening of response observed over time, with ongoing monitoring for progression-free survival and duration of response.

• Additional data from VMT-α-NET expected at ASCO and a major conference later in the year, including updates from higher dose cohorts.

Safety profile and manufacturing

• Safety profile remains favorable compared to competitors, attributed to proprietary chelator and drug design.

• No significant kidney toxicity observed; design minimizes risk of unbound metabolites affecting healthy tissue.

• Manufacturing network expansion underway, with a new Chicago facility expected to support phase III and commercial supply, followed by additional sites in LA and Houston.

• Drug is delivered ready-to-use, facilitating broader adoption beyond academic centers.